Enzalutamide versus abiraterone as a first-line endocrine therapy for castrationresistant prostate cancer (ENABLE study for PCa): A study protocol for a multicenter randomized phase III trial

Both enzalutamide and abiraterone have demonstrated improved radiographic progression-free and overall survival for castration-resistant prostate cancer (CRPC) compared with placebo controls before docetaxel treatment in phase III studies. | Enzalutamide versus abiraterone as a first-line endocrine therapy for castrationresistant prostate cancer ENABLE study for PCa A study protocol for a multicenter randomized phase III trial

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN